For the quarter, sales from the Amesa geography stood at Rs 235.63 crore and accounted for 36% of the total sales. PBIT from the same stood at 34.59 crore up by 12% YoY and accounted for 48% of total PBIT.

For the quarter, sales from the EAP geography stood at Rs 156.35 crore and accounted for 24% of total sales and PBIT from the same stood at Rs 20.75 crore down by 6% YoY.

For the quarter, sales from the America geography stood at Rs 132.86 crore and PBIT from the same stood at Rs 14.99 crore up by 103% YoY.

For the quarter, sales from the EU geography stood at Rs 129.31 crore and PBIT stood at Rs 1.94 crore up by 8% YoY.

Revenue growth helped by increased offtake in US & Egypt by key customers and EDG continue to deliver after the integration.

China's efforts for laminate exports to external customers have materialized in new geographies.

India business commenced the First phase of commercial production at its new unit in Kamrup, Assam w.e.f. 23 July 2018. The size of investment in phase-I is over Rs. 60 crore. Spread across 70,000 sq.ft. and this Greenfield investment is planned for production of 750 million laminated tubes per annum when it is fully completed. In the first phase, the facility is equipped to produce 200 million tubes per annum and will ramp up to 750 million tubes over a span of 18 months.

India standalone revenue grew 6.3% compared to same quarter last year. The revenue growth would have been higher but for inventory correction by key customers and also due to change in regulations for pharma category requiring prominent display of generic name vis-à-vis brand name, leading to change in the artwork of packaging material. The offtake of pharma customers will continue to get impacted in second and part of third quarter also.

Net Debt as at June 18 end stood at Rs 601.01 crore.

Overall

The new unit in Assam is a strategic investment, in-line with company's stated objective of ‘go and grow' with customers. Several of our customers have set up units in Assam and our presence near them will facilitate servicing them better, besides opening up opportunities for developing markets in North-East India and surrounding countries.

The quarter has seen increased offtake from key customers in US, Egypt and Germany. New business pipeline development efforts during last year are beginning to yield results across geographies. The effect of which will be seen beginning next calendar year. Impact on India revenue due to change in pharma regulations should get over by third quarter of this financial year.

Performance for the 12 months ended Mar 18

FY 17 financials include financials of EDG Germany from Oct 16 onwards and hence 12 months ended Mar 18 results and FY 17 financials are not comparable on YoY basis.

For the 12 months ended Mar 18, consolidated net sales stood at Rs 2423.88 crore. OPM stood at 19.2% resulting an OP of Rs 464.75 crore. Other income stood at Rs 26.37 crore. Interest cost and depreciation cost stood at Rs 54.91 crore and Rs 167.07 crore respectively. PBT stood at Rs 269.14 crore. There was a MTM forex loss of Rs 4.98 crore in FY 18. After providing total tax of Rs 88.91 crore and loss of share of associates of Rs 3.65 crore, consolidated PAT for 12 months ended Mar 18 stood at Rs 171.60 crore.

For the 12 months ended Mar 18, sales from the Amesa geography stood at Rs 934.84 crore PBIT from the same stood at 141.23 crore.

For the 12 months ended Mar 18, sales from the EAP geography stood at Rs 574.37 crore and PBIT from the same stood at Rs 90.50 crore.

For the 12 months ended Mar 18, sales from the America geography stood at Rs 488.46 crore and PBIT from the same stood at Rs 61.12 crore.

For the 12 months ended Mar 18, sales from the EU geography stood at Rs 509.49 crore and PBIT from the same stood at Rs 12 crore.